drugset
drugset / Trial / NCT04844411

A Study of JNJ-67835989 in Healthy Participants

NCT04844411 ↗

Phase 1 Completed 109 enrolled Janssen Research & Development, LLC
RandomizedSequentialDouble-blindOther

Summary

The purpose of this study is to investigate the safety and tolerability of JNJ-67835989 versus placebo after single (or divided) oral dose administration (ascending dose levels) in healthy participants, pharmacokinetics (PK) of JNJ-67835989 in plasma and urine after single (or divided) oral dose administration in healthy participants, effects of JNJ-67835989 following single (or divided) oral dose administration in healthy participants on cardiovascular parameters, effects of JNJ-67835989 following single (or divided) oral dose administration on dissociative symptoms in healthy participants, and sedative effects of JNJ-67835989 following single (or divided) oral dose administration in healthy participants.

Timeline

Start
2021-04-27
Primary completion
2022-05-18
Completion
2022-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-67835989 Unknown — Oral

Indications

No indication recorded.